

May 07, 2026

National Stock Exchange of India Limited  
Exchange Plaza  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400051  
**(SYMBOL: THYROCARE)**

BSE Limited  
Phiroze Jeejeeboy Towers  
Dalal Street,  
Mumbai- 400001  
**(SCRIP CODE: 539871)**

**Sub: Investor Presentation on Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026.**

**Ref: Disclosure under Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/ Madam,

We are enclosing herewith a copy of the Investor Presentation on the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2026.

The same is also being made available on the Company's website <https://investor.thyrocare.com/>

We request you to please take the same on record.

Yours Faithfully,  
For **Thyrocare Technologies Limited,**



**Brijesh Kumar**  
Company Secretary and Compliance Officer

Encl. A/a

# Thyrocare Earnings Presentation

Q4FY26 & FY26



## Safe Harbour Statement

---

Statements in this presentation describing the Company's performance may be "forward looking statements" within the meaning of applicable security laws and regulations. Actual results may differ materially from those directly or indirectly expressed, inferred or implied. Important factors that could make a difference to the Company's operations include, among others, economic conditions affecting demand/supply and price conditions in the market, changes in or due to the environment, Government regulations, laws, statutes, judicial pronouncements and/or incidental factors.

# Agenda

---

01 **Latest updates**

02 **Performance highlights**

03 **Financial performance**

04 **Going forward strategy**


# Q4FY26 - Delivered 20% YoY revenue and 31% YoY EBITDA growth with highest quality standards

## Financial Parameters




	<b>Consolidated Revenue</b>	<b>224 Cr</b> (+20% YoY)
	<b>Standalone Revenue</b>	<b>211 Cr</b> (+21% YoY)
	<b>Franchisee Revenue</b>	<b>128 Cr</b> (+21% YoY)
	<b>Partnership Revenue</b>	<b>72 Cr</b> (+23% YoY)



## Operational Parameters

	<b>Quarterly Active Franchisee</b>	<b>~10,800</b> (+15% YoY)
	<b>Patients</b>	<b>5.1 Mn</b> (+21% YoY)

## Quality Parameters

	<b>Samples Processed in NABL Labs</b>	<b>97%</b>
	<b>Tests Conducted</b>	<b>59.0 Mn</b> (+29% YoY)
	<b>Complaints Per Mn Tests</b>	<b>3.1</b> (34% Down YoY)

**Revenue: +20% YoY ↑**

**Reported EBITDA: +31% YoY ↑**

**PAT: +128% YoY ↑**

Note: Tanzania operations have been fully consolidated as a subsidiary in the current financial year

# FY26 - Delivered 21% YoY revenue and 39% YoY EBITDA growth with highest quality standards

## Financial Parameters

 Consolidated Revenue **829 Cr**  
(+21% YoY)

 Standalone Revenue **774 Cr**  
(+22% YoY)

 Franchisee Revenue **477 Cr**  
(+18% YoY)

 Partnership Revenue **254 Cr**  
(+32% YoY)

## Operational Parameters

 Thyrocare Branded Franchisees **~1,350**

 Patients **19.2 Mn**  
(+15% YoY)

 Test Menu Offerings **1,275 tests**  
(+39% YoY)

 New Technology Addition

- Next Gen sequencing
- ImmunoCAP
- BioFire Panels

## Quality Parameters

 Samples Processed in NABL Labs **96%**

 Tests Conducted **209.6 Mn**  
(+23% YoY)

 Complaints Per Mn Tests **3.5**  
(51% Down YoY)

Revenue: **+21% YoY ↑**

Reported EBITDA: **+38% YoY ↑**

PAT: **+81% YoY ↑**

Note: Tanzania operations have been fully consolidated as a subsidiary in the current financial year

# Expanding capabilities through lab additions and new service launches

Launching Our New Specialty Range in

## Genomics

Starting with NIPT

HerCheck NIPT  
(NIPT1)



## Mega Launch

Allergy Testing (By Phadia)

Now In-House

2 Phadiatop Tests  
15 Panels | 84 Individual Allergens



Inhalants



Food (Veg &  
Non-Veg)



Comprehensive  
Profiles



## Lab Network Expansion in FY26

- Bhagalpur
- Davangere
- Kashmir
- Roorkee
- Gwalior
- Vijayawada
- Mandi



Patient  
Trust



Stronger  
Network



Operating  
Leverage

# Brand Elevation through endorsement and national recognition

## Onboarded Madhuri Dixit as brand ambassador



## Recognized with 2 National Awards at Voice of Healthcare Forum



# Nationwide lab network dedicated to making good quality diagnostics accessible and affordable to all



## India Labs (40) :

- ▶ **West (9) :** Mumbai (3), Pune, Raipur, Ahmedabad, Nagpur, Goa, Surat
- ▶ **East (6) :** Kolkata, Bhubaneswar, Guwahati, Patna, Ranchi, Bhagalpur
- ▶ **North (15) :** Noida, Bhopal, Jaipur, Delhi, Lucknow, Varanasi, Indore, Amritsar, Mohali, Ambala, Sundernagar, Kashmir, Roorkee, Mandi, Gwalior
- ▶ **South (10) :** Bangalore (2), Coimbatore, Kochi, Chennai, Hyderabad, Vizag, Vijaywada, Tirupati, Davanagere

## International Lab (1) : Tanzania (1)

## SPEED

Reports released within average TAT of



**3.43**  
**HOURS**

of sample reaching the lab

## QUALITY

Complaints dropped to

**3.06** Per Million Tests,

Down

**34% YoY**



Reports verified by expert

**MD Pathologists**

Stationed in Every Lab

## TRUST

**9/10**

**DOCTORS**



*trust that*

**Thyrocare** reports are **Accurate & Reliable\***

Note: We were India's first diagnostic chain to achieve 100% NABL accreditation across all labs in Q4FY25

\*As per a survey on doctors' perception of laboratory diagnostics (IJARIIT, 2023)

# Strengthening our relationships with channel partners

In FY26, Thyrocare conducted 13 franchisee meetings Pan-India, capturing feedback from 750+ franchisees across locations. These insights were used to strengthen processes, service delivery, and overall quality outcome



# Strengthening our relationships with doctors

In FY26, Thyrocare conducted 9 doctor meets and enabled lab visits, capturing insights from 300+ doctors Pan-India. These interactions helped showcase our quality systems, advanced equipment, and strengthen awareness of our capabilities while addressing key gaps



# Agenda

---

01 Latest updates

02 **Performance highlights**

03 Financial performance

04 Going forward strategy

# Financial Performance Q4FY26



YoY TTL Consolidated Revenue

+20% ↑

YoY Pathology Revenue

+21% ↑

YoY Reported EBITDA

+31% ↑

Reported EBITDA margin

34%

YoY PAT

+128% ↑

PAT margin

22%

*Note : Tanzania operations have been fully consolidated as a subsidiary in the current financial year*

# Financial Performance FY26



YoY TTL Consolidated Revenue

+21% ↑

YoY Pathology Revenue

+22% ↑

YoY Reported EBITDA

+38% ↑

Reported EBITDA margin

32%

YoY PAT

+81% ↑


PAT margin

20%


*Note : Tanzania operations have been fully consolidated as a subsidiary in the current financial year*

# FY26 - Strong and consistent growth outlined by key metrics


Tests performed (Mn)




Patients (Mn)




Quarterly active franchisees (#)




Revenue per test (INR)<sup>1,2</sup>



Revenue per patient (INR)<sup>2</sup>



Tests per patient (#)




<sup>1</sup> Total tests conducted, revised to include Polo, Vimta test count


<sup>2</sup> Excludes material and others revenue

# 20% YoY revenue growth in overall business and 31% YoY growth in Reported EBITDA in Q4FY26

## Consolidated Revenue (INR Cr)



## Reported EBITDA (INR Cr)



EBITDA%	Q4FY25	Q1FY26	Q2FY26	Q3FY26	Q4FY26
	31%	30%	33%	29%	34%


	YoY Growth%
Pathology	+22%
Radiology	-9%

	YoY Growth%
Pathology	+31%
Radiology	+23%


Note: Tanzania operations have been fully consolidated as a subsidiary in the current financial year  
Radiology Revenue and EBITDA include Pulse Hi tech business

# Franchisee business now accelerating and catching up with partnership business

## Pathology Revenue<sup>1</sup> (Rs Cr)



## Pathology Vials (Lakhs)



—●— Franchise   
 —●— Partnership   
 —●— D2C


<sup>1</sup> In Q4FY25 – one-off camp revenue of Mahakumbh and insurance activations, excluding from the Q4FY25 base – normalized partnerships growth is 32% (in line with Q1-Q3 FY26 partnership growth)

<sup>2</sup> Standalone Pathology business including materials & other revenue, corresponding figures restated accordingly,

Note : The above numbers do not include Tanzania business

# Sustained network expansion drives franchisee base to a record high of ~10,800 in Q4FY26

## Journey of Quarterly active franchisee count (FY21 to FY26)



## Sustained franchise success driving superior growth

### Franchise Cohorts : Revenue per retained franchise from FY22 to FY26, rebased to 1

Year	Y1	Y2	Y3	Y4	Y5
FY22	1.0x	2.6x	3.4x	4.1x	5.1x
FY23	1.0x	2.4x	3.3x	3.9x	
FY24	1.0x	2.6x	3.3x		
FY25	1.0x	2.5x			
FY26	1.0x				

- ▶ Revenue per retained franchise has been consistently growing for the franchise added post FY22. The initiatives causing the growth are:
  - ▶ Slab based pricing model which increased motivation amongst franchisee to add volume
  - ▶ Enhanced quality with NABL-accredited lab processing and a reduced TAT
  - ▶ Strengthening our relationships with doctors and channel partners
  - ▶ Test menu expansion by introducing specialized tests to portfolio

# Agenda

---

01 Latest updates

02 Performance highlights

03 **Financial performance**

04 Going forward strategy

# Income statement - TTL Standalone : Jump in PAT by 101% YoY

INR crore	Quarter			Financial Year		
	Q4FY26	Q4FY25	YoY	FY26	FY25	YoY
Revenue from operations	210.67	173.87	21%	774.27	633.10	22%
Cost of materials consumed/sold	(54.53)	(46.95)		(209.23)	(180.08)	
<b>Gross margin</b>	<b>156.14</b>	<b>126.92</b>	<b>23%</b>	<b>565.04</b>	<b>453.02</b>	<b>25%</b>
Employee benefit expenses	(30.27)	(24.28)		(111.68)	(99.82)	
Other expenses	(49.79)	(39.72)		(182.57)	(146.37)	
Provision for receivables	(0.28)	(0.23)		2.15	(1.09)	
<b>Normalized EBITDA</b>	<b>75.80</b>	<b>62.69</b>	<b>21%</b>	<b>272.94</b>	<b>205.74</b>	<b>33%</b>
ESOP cost <sup>1</sup>	(3.17)	(7.36)		(16.61)	(19.70)	
<b>Reported EBITDA</b>	<b>72.63</b>	<b>55.33</b>	<b>31%</b>	<b>256.33</b>	<b>186.04</b>	<b>38%</b>
Depreciation and amortisation	(12.94)	(11.78)		(51.17)	(46.52)	
Finance cost	(1.43)	(0.62)		(2.18)	(2.63)	
Other income	3.72	4.56		13.39	13.34	
<b>PBT and exceptional items</b>	<b>61.98</b>	<b>47.49</b>	<b>31%</b>	<b>216.37</b>	<b>150.23</b>	<b>44%</b>
Share in profit in Associate & JV entity	-	-		-	-	
Exceptional items	-	(11.16)		(5.97)	(11.16)	
<b>PBT</b>	<b>61.98</b>	<b>36.33</b>	<b>71%</b>	<b>210.40</b>	<b>138.97</b>	<b>51%</b>
Tax expense	(18.40)	(14.61)		(61.59)	(44.02)	
<b>Profit after tax</b>	<b>43.58</b>	<b>21.72</b>	<b>101%</b>	<b>148.81</b>	<b>95.05</b>	<b>57%</b>
<b>Profit after tax w/o exceptional items</b>	<b>43.58</b>	<b>32.88</b>	<b>33%</b>	<b>154.78</b>	<b>106.21</b>	<b>46%</b>
Gross margin %	74%	73%		73%	72%	
Normalized EBITDA%	36%	36%		35%	32%	
Reported EBITDA%	34%	32%		33%	29%	
PAT%	21%	12%		19%	15%	
PAT% W/o Exceptional	21%	18%		20%	16%	

<sup>1</sup> Pertains to parent company ESOPs

Note : The above numbers do not include Tanzania business

**Revenue** grew by 21% YoY, Franchise 21%; Partnerships 23%

**Gross margin** improved 114 bps YoY

**Reported EBITDA** grew by 31% YoY

**Employee benefit expenses** increased YoY on account of annual increments and increase in headcounts with new lab openings and investments in specialty menu expansion

**Other overheads** increased in line with Revenue

**Reported EBITDA margin** at 34%  
260bps up from last year

## Income statement - NHL Standalone

INR crore	Quarter			Financial year		
	Q4FY26	Q4FY25	YoY	FY26	FY25	YoY
Revenue from operations	10.31	11.89	(13%)	44.62	47.59	(6%)
Cost of materials consumed/sold	(2.01)	(2.36)		(9.08)	(10.46)	
<b>Gross margin</b>	<b>8.30</b>	<b>9.53</b>	<b>(13%)</b>	<b>35.54</b>	<b>37.13</b>	<b>(4%)</b>
Employee benefit expenses	(1.35)	(1.32)		(5.18)	(5.48)	
Other expenses	(4.44)	(5.80)		(22.57)	(26.60)	
Provision for receivables	(0.01)	(0.03)		(0.23)	(0.15)	
<b>Normalized EBITDA</b>	<b>2.50</b>	<b>2.38</b>	<b>5%</b>	<b>7.56</b>	<b>4.90</b>	<b>54%</b>
ESOP cost <sup>1</sup>	(0.26)	(0.54)		(1.21)	(1.03)	
<b>Reported EBITDA</b>	<b>2.24</b>	<b>1.84</b>	<b>22%</b>	<b>6.35</b>	<b>3.87</b>	<b>64%</b>
Depreciation and amortisation	(0.96)	(1.54)		(4.89)	(7.10)	
Finance cost	(0.09)	(0.13)		(0.34)	(0.57)	
Other income	1.38	0.94		4.88	3.33	
<b>PBT and exceptional items</b>	<b>2.57</b>	<b>1.11</b>	<b>132%</b>	<b>6.00</b>	<b>(0.47)</b>	<b>1177%</b>
Exceptional items	-	-		(0.19)	-	
<b>PBT</b>	<b>2.57</b>	<b>1.11</b>	<b>132%</b>	<b>5.81</b>	<b>(0.47)</b>	<b>1337%</b>
Tax expense	(0.13)	(0.06)		0.35	0.47	
<b>Profit after tax</b>	<b>2.44</b>	<b>1.05</b>	<b>132%</b>	<b>6.16</b>	<b>0.00</b>	
<b>Profit after tax w/o exceptional items</b>	<b>2.44</b>	<b>1.05</b>	<b>132%</b>	<b>6.16</b>	<b>0.00</b>	

Gross margin %	81%	80%		80%	78%	
Normalized EBITDA%	24%	20%		17%	10%	
Reported EBITDA%	22%	16%		14%	8%	
PAT%	24%	9%		14%	0%	
PAT% W/o Exceptional	24%	9%		14%	0%	

<sup>1</sup> Pertains to parent company ESOPs

Note : The above numbers do not include Pulse Hi Tech

**Revenue** declined 13%, reflecting a strategic exit from non-profitable centers

**Reported EBITDA** grew by 22%

**Profit after Tax** grew YoY 132%, driven by higher other income.

# Income statement - TTL Consolidated : Jump in PAT by 128% YoY

	Quarter			Financial Year		
	Q4FY26	Q4FY25	YoY	FY26	FY25	YoY
<b>INR crore</b>						
Revenue from operations	223.95	187.16	20%	829.04	687.35	21%
Cost of materials consumed/sold	(56.68)	(49.47)		(219.57)	(191.08)	
<b>Gross margin</b>	<b>167.27</b>	<b>137.69</b>	<b>21%</b>	<b>609.47</b>	<b>496.27</b>	<b>23%</b>
Employee benefit expenses	(32.64)	(25.88)		(120.24)	(107.07)	
Other expenses	(55.83)	(46.22)		(211.24)	(177.88)	
Provision for receivables	(0.28)	(0.30)		1.87	(1.26)	
<b>Normalized EBITDA</b>	<b>78.52</b>	<b>65.29</b>	<b>20%</b>	<b>279.86</b>	<b>210.06</b>	<b>33%</b>
ESOP cost <sup>1</sup>	(3.43)	(7.90)		(17.82)	(20.73)	
<b>Reported EBITDA</b>	<b>75.09</b>	<b>57.39</b>	<b>31%</b>	<b>262.04</b>	<b>189.33</b>	<b>38%</b>
Depreciation and amortisation	(14.03)	(13.77)		(58.58)	(55.26)	
Finance cost	(1.52)	(0.70)		(2.80)	(3.05)	
Other income	4.31	4.59		16.99	14.83	
<b>PBT and exceptional items</b>	<b>63.85</b>	<b>47.51</b>	<b>34%</b>	<b>217.65</b>	<b>145.85</b>	<b>49%</b>
Share in profit in Associate & JV entity	0.58	(0.63)		1.39	(1.44)	
Exceptional items	-	(11.16)		(6.16)	(11.16)	
<b>PBT</b>	<b>64.43</b>	<b>35.72</b>	<b>81%</b>	<b>212.88</b>	<b>132.25</b>	<b>60%</b>
Tax expense	(15.73)	(14.38)		(50.03)	(43.27)	
<b>Profit after tax</b>	<b>48.70</b>	<b>21.34</b>	<b>128%</b>	<b>162.85</b>	<b>89.98</b>	<b>81%</b>
<b>Profit after tax w/o exceptional items</b>	<b>48.70</b>	<b>32.50</b>	<b>50%</b>	<b>169.01</b>	<b>101.14</b>	<b>67%</b>
Gross margin %	75%	74%		74%	72%	
Normalized EBITDA%	35%	35%		34%	31%	
Reported EBITDA%	34%	31%		32%	28%	
PAT%	22%	11%		20%	13%	
PAT% W/o Exceptional	22%	17%		20%	14%	

<sup>1</sup> Pertains to parent company ESOPs. Basis the current allotted pool, expected cost for next 3 years is : FY27 – 12.8Cr, FY28 – 6.7Cr, FY29 – 3.3Cr  
The consolidated results include TTL (standalone), NHL, and other subsidiaries & associates. Tanzania operations have been fully consolidated as a subsidiary in the current financial year

Revenue grew by 20% YoY

Gross margin improved 113 bps YoY

Reported EBITDA grew by 31% YoY

Employee benefit expenses increased YoY on account of annual increments and increase in headcounts with new lab openings and investments in specialty menu expansion

Other overheads increased in line with Revenue

Reported EBITDA at 34% 288bps up from last year

# Balance Sheet - TTL Consolidated

INR crore	Mar26	Mar25	INR crore	Mar26	Mar25
<b>Non-current assets</b>			<b>Equity</b>		
Property, plant & equipment	145.08	148.71	Equity share capital	159.17	52.99
Capital work-in-progress	3.06	14.15	Other equity	426.33	493.76
Goodwill	108.21	108.21	Non-controlling interests	0.52	0.30
Other intangible assets	3.49	4.84	<b>Total equity (i)</b>	<b>586.02</b>	<b>547.05</b>
Right of use assets	60.54	35.45	<b>Non-current liabilities</b>		
Investment in associate and joint venture	25.14	24.17	<b>Financial liabilities</b>		
<b>Financial assets</b>			(i) Lease liabilities	39.18	16.92
Other financial assets	6.66	7.89	Provisions	12.11	6.94
Deferred tax assets (net)	15.66	8.53	<b>Total non-current liabilities (ii)</b>	<b>51.29</b>	<b>23.86</b>
Non-current tax assets (net)	4.31	1.65	<b>Current liabilities</b>		
Other non-current assets	2.78	1.43	<b>Financial liabilities</b>		
<b>Total non-current assets (i)</b>	<b>374.93</b>	<b>355.03</b>	(i) Lease liabilities	11.51	7.76
<b>Current assets</b>			(ii) Trade payables	65.37	76.21
Inventories	48.46	46.54	(iii) Other financial liabilities	14.45	16.60
<b>Financial assets</b>			Contract liabilities	10.69	13.63
(i) Investments	151.50	137.36	Current tax liabilities (net)	2.38	2.38
(ii) Trade receivables	73.88	73.00	Provisions	1.46	1.00
(iii) Cash and cash equivalents	38.32	17.68	Other current liabilities	4.05	4.26
(iv) Bank balances other than above	29.84	36.80	<b>Total current liabilities (iii)</b>	<b>109.91</b>	<b>121.84</b>
(iv) Other financial assets	2.25	1.15	<b>Total liabilities (iv=ii+iii)</b>	<b>161.20</b>	<b>145.70</b>
Other current assets	28.04	25.19	<b>Total equity and liabilities (i+iv)</b>	<b>747.22</b>	<b>692.75</b>
<b>Total current assets (ii)</b>	<b>372.29</b>	<b>337.72</b>			
<b>Total assets (i+ii)</b>	<b>747.22</b>	<b>692.75</b>			

# Cash Flow Statement - TTL Consolidated : Operating Cash flow generated in FY26 was INR 213.24 Cr

INR crore	Annual	
	FY26	FY25
<b><u>A. Cash flow from operating activities</u></b>		
Profit before tax	212.88	146.88
Non-cash items and other adjustments	68.64	73.28
Changes in working capital	(8.46)	11.13
Income tax paid (net of refunds)	(59.82)	(51.38)
<b>Net cash flow generated/(used) from operating activities (i)</b>	<b>213.24</b>	<b>179.91</b>
<b><u>B. Cash flow from investing activities</u></b>		
Purchase of PPE, CWIP and intangible assets	(20.88)	(33.48)
Proceeds from sale of PPE, CWIP	5.40	0.01
Net (purchase)/sale of current investments and term deposits	(6.43)	8.20
Consideration paid on purchase of Polo and Vimta Clinical Diagnostics	-	(11.26)
Investment into Associates & Jointly Controlled Entity	-	0.01
Interest received	3.07	1.97
(Investment in)/proceeds from maturity of term deposits	(4.17)	(6.56)
<b>Net cash flow generated/(used) from investing activities (ii)</b>	<b>(22.51)</b>	<b>(41.11)</b>
<b><u>C. Cash flow from financing activities</u></b>		
Net proceeds/(repayment) of borrowings	-	(21.59)
Dividend paid to the shareholders	(148.43)	(95.31)
Others	(21.16)	(13.52)
<b>Net cash flow generated/(used) from financing activities (iii)</b>	<b>(169.59)</b>	<b>(130.42)</b>
<b>Net increase/(decrease) in cash &amp; cash equivalents (iv=i+ii+iii)</b>	<b>20.64</b>	<b>8.38</b>
Cash & cash equivalents at the beginning of the year (v)	17.68	9.30
<b>Cash &amp; cash equivalents at the end of the year (iv+v)</b>	<b>38.32</b>	<b>17.68</b>

**Operating activities** : Incremental cash generated from the operating activities stands at INR 213.2 Cr.

**Investing activities** : Capex invested of Rs. 20.9Cr on account of infrastructure addition and replacement of machines

**Financing activities** : Dividend payout during the year of Rs.148.4Cr. Other item includes repayment of lease

# Agenda

---

01 Latest updates

02 Performance highlights

03 Financial performance

04 **Going forward strategy**



Global in our reach, excellence in our experience



To make good quality diagnostics affordable to all

## Going forward - Key pillars of growth

---

### FRANCHISE

- ▶ Going deeper into India with focused test menu
- ▶ Strengthening our existing franchise network with focus on large service providers

### PARTNERSHIPS

- ▶ Expanding our partnerships towards insurance and ECG at home
- ▶ Strengthen and further grow our network of partner relationships

### INTERNATIONAL EXPANSION

- ▶ Strengthening our presence in Tanzania to deliver accessible, high quality, and affordable diagnostic testing services

Our pathology strategy remains to be a B2B service provider with an **affordable value driven model based on scale efficiencies**



**Thyrocare is well placed to leverage best of both worlds**



Revenue contribution in pathology business

+ Direct to Consumer Business at **5%**



Tests you can trust

**For Any queries, please reach out to**  
[investor\\_relations@thyrocare.com](mailto:investor_relations@thyrocare.com)

# Thank You

*Disclaimer*

*This presentation is for information purposes only and it contains general background information about the Company's activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development, information or events, or otherwise. This Presentation comprises information given in summary form and does not purport to be complete. This Presentation should not be considered as a recommendation to any investor to purchase the equity shares of the Company. This Presentation includes statements that are, or may be deemed to be, "forward-looking statements". By their nature, forwardlooking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future financial condition and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved. The past performance is not indicative of future results. This document has not been and will not be reviewed or approved by the statutory auditors or a regulatory authority in India or by any stock exchange in India.*